A big change is coming for gamblers in the U.S.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
The AI Startup Legora has taken a bold leap forward by announcing a major funding round that places its valuation at around $1.8 billion. This milestone marks an important moment for this legal-tech innovator, and sends a strong signal to investors and the tech world about the shifting terrain of AI, enterprise software and the…
Novo Nordisk is making headlines again. We saw its shares rise after the FDA approved Wegovy for a serious liver condition called MASH, or metabolic dysfunction-associated steatohepatitis. This recent approval is significant since Wegovy, previously known for weight management, can now also treat adults with moderate to advanced liver fibrosis. The news sparked optimism in…
We are entering an important week for the markets. U.S. stock futures are holding steady, with Dow futures slightly higher, while S&P 500 and Nasdaq futures show mixed movements. Investors are focused on the CPI Data, the Consumer Price Index, along with the upcoming jobs report. Both releases have the potential to shift market sentiment,…
The Sensex climbed more than 100 points, and the Nifty 50 pushed past the 25,800 level on Thursday, February 19, 2026, driven by strong buying in IT shares and positive market mood. We from this desk saw Indian benchmark indices extend their gains for the fourth straight session, showing renewed investor confidence and sector‑specific strength….
NTPC, India’s top power producer, saw its stock take a hit recently. NTPC shares fall 4% after a big equity transfer shook the stock market. This drop has investors curious about what’s next for the company. Continue Reading on Meyka This article is available in full on our main platform. Get access to complete analysis,…
Novo Nordisk, the Danish pharmaceutical giant known for diabetes and obesity treatments, announced impressive new clinical trial results in collaboration with United Biotechnology for an experimental obesity drug called UBT251. The mid‑stage trial reported a mean weight loss of up to 19.7% after 24 weeks, significantly outperforming the placebo group, which saw just 2.0% weight…